Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Apollomics, after giving up on leukemia drug, posts ph. 3 fail
The failure of Apollomics’ leukemia drug in a phase 3 trial isn’t a shock to the biotech, which had already given up on the E-selectin inhibitor
James Waldron
Dec 20, 2024 9:30am
Roche's Prothena-partnered Parkinson's prospect fails phase 2b
Dec 19, 2024 4:31am
Foghorn drops sole wholly owned clinical asset after AML failure
Dec 16, 2024 7:48am
Incyte scraps cancer-related anemia program after ph. 1/2 fail
Dec 13, 2024 2:30pm
Corcept's cortisol modulator fails to slow ALS decline in ph. 2
Dec 12, 2024 7:05am
Anaptys scraps atopic dermatitis asset after ph. 2 fail
Dec 11, 2024 11:02am
